Predictive Oncology Closes Registered Direct Offering
Predictive Oncology Inc. (NASDAQ: POAI) has recently completed a significant step in bolstering its financial foundation by closing a registered direct offering. This move allows the company to enhance its operations in AI-driven drug discovery and biologics. The offering comprised the sale of 363,336 shares of common stock at an attractive purchase price of $1.50 per share, adhering to market conditions as regulated by Nasdaq rules.
Details of the Offering
The undertaking was facilitated by H.C. Wainwright & Co., serving as the exclusive placement agent for this offering. The gross proceeds from this financial endeavor amounted to approximately $545,004 before considering the placement agent fees and various associated expenses. The net funds obtained from the offering will be allocated primarily for working capital and general corporate purposes, which is crucial for sustaining its innovative projects.
Regulatory Framework
The shares offered were made available under a “shelf” registration statement on Form S-3, which was approved by the Securities and Exchange Commission (SEC). This regulatory framework allows Predictive Oncology to have greater flexibility in managing their equity capital. A final prospectus supplement concerning the registered offering was filed with the SEC, ensuring full compliance with legal requirements.
About Predictive Oncology
Predictive Oncology stands out as a pioneer in utilizing cutting-edge artificial intelligence and machine learning technologies to streamline the early drug discovery process. With a mission to serve cancer patients worldwide, the company’s flagship AI platform, PEDAL, has demonstrated an impressive accuracy rate of 92% in predicting tumor responses to specific drug compounds. This remarkable capability empowers researchers to make informed choices regarding drug-tumor combinations, enhancing their testing efficacy.
The Company's Biobank and Resources
Further supporting their research initiatives, Predictive Oncology boasts a comprehensive biobank, containing over 150,000 assay-capable heterogeneous human tumor samples. This extensive resource positions the company uniquely within the industry, providing partners with unparalleled access to sophisticated AI-based drug discovery solutions. Additionally, the company operates a fully owned Clinical Laboratory Improvement Amendments (CLIA) laboratory facility, ensuring high-quality and reliable testing services.
Looking Ahead
The funds generated from this direct offering signify a vital opportunity for Predictive Oncology to leap forward in developing its innovative technologies. As they continue to enhance their capabilities in drug discovery, the company plays a crucial role in transforming cancer treatment paradigms. By supporting ongoing operations through this successful financial strategy, Predictive Oncology is well-positioned to fulfill its commitment to advancing healthcare with AI integration.
Contact Information
For those interested in further details, individuals can reach out to the company’s Investor Relations contact, Tim McCarthy, who is associated with LifeSci Advisors, LLC. For inquiries, you can email him directly to gain insights into the company’s future plans and technological advancements.
Frequently Asked Questions
What is the purpose of the recent offering by Predictive Oncology?
The funds raised are intended for working capital and general corporate purposes, helping to sustain and enhance their innovative projects in drug discovery.
Who acted as the placement agent for this offering?
H.C. Wainwright & Co. acted as the exclusive placement agent for Predictive Oncology's registered direct offering.
What is the significance of the AI platform PEDAL?
PEDAL is designed to predict tumor responses to drug compounds with 92% accuracy, aiding in precise drug-tumor combination selections for research.
How does Predictive Oncology’s biobank contribute to their mission?
The biobank, containing over 150,000 tumor samples, provides a unique resource for partners, enhancing the quality and reach of their drug discovery efforts.
Where is Predictive Oncology headquartered?
Predictive Oncology is headquartered in Pittsburgh, PA, where it drives its innovative research and development in the healthcare sector.
